Life Sciences

  • September 14, 2026

    Ex-Perrigo VP Escapes Some Price-Fixing Claims From AGs

    A Connecticut federal judge has tossed most of the claims against a former Perrigo executive in sprawling generic-drug price-fixing litigation brought by state enforcers, holding there is insufficient evidence he entered into antitrust conspiracies related to more than a dozen dermatological drugs, but teeing up a handful of other claims for trial.

  • September 14, 2026

    NY Village Can Pursue PFAS Claims Against Local Cos.

    A New York federal judge won't let a group of manufacturing and industrial companies out of a suit by the Village of Nyack alleging they contaminated the water supply with so-called forever chemicals, saying the allegations in the complaint make a plausible claim under state and federal environmental law.

  • September 14, 2026

    Feds Want Justices To Skip Google 'Settled Expectations' Row

    The federal government is telling the U.S. Supreme Court that Google didn't meet the appropriate standard to get the Federal Circuit to look at the company's challenge to the U.S. Patent and Trademark Office's policy of using the age of patents as a reason not to review them.

  • September 14, 2026

    Former Trump Assistant To Co-Lead Covington Policy Practice

    Covington & Burling LLP said Monday the firm has hired a former assistant to President Donald Trump, who served in the president's first administration as director of the Domestic Policy Council and most recently owned a federal consulting business in Washington, D.C.

  • September 14, 2026

    Abbott To Pay $385M To End FCA Claims Over Infant Formula

    The U.S. Department of Justice on Monday said that Abbott Laboratories has agreed to pay nearly $385 million to end False Claims Act allegations over the manufacture of contaminated infant formula at locations in Michigan and Arizona.

  • September 14, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court this past week saw disputes over allegedly fabricated board approvals at a telecom infrastructure startup, insider trading and child safety at Roblox Corp. and ownership of artificial intelligence technology used in legal proceedings.

  • September 11, 2026

    Tylenol Maker Seeks 2nd Circ. Relook In Autism, ADHD Suits

    Tylenol maker Kenvue and several retailers have urged the Second Circuit to revisit its decision overturning a district court's exclusion of expert testimony for plaintiffs who claim prenatal exposure to the over-the-counter pain reliever causes autism and ADHD, saying the appeals court improperly restricted the trial court's "gatekeeping role."

  • September 11, 2026

    Exploding Home Sauna Suit Clears Damages Concerns

    A New Jersey woman will get to proceed with her product liability lawsuit claiming an at-home sauna spontaneously exploded, after a federal judge accepted Friday her argument that a jury could award her tens of millions of dollars, so the amount in controversy would not fall below the statutory minimum.

  • September 11, 2026

    AbbVie Seeks To Nix Health Orgs.' 'New Theory' In 340B Row

    Two advocacy groups for safety net health providers shouldn't be allowed to argue that a D.C. federal court lacks jurisdiction over biopharmaceutical company AbbVie Inc.'s suit challenging the federal government's definition of a "patient" in the 340B drug discount program, AbbVie told the court.

  • September 11, 2026

    Abbott Can Move Baby Formula Death Suit Out Of Illinois

    An Illinois state appeals court on Friday ordered the dismissal of a product liability suit alleging Abbott Laboratories' Similac formula caused a premature Florida infant's fatal case of necrotizing enterocolitis, finding the case belongs in Florida rather than Chicago's Cook County.

  • September 11, 2026

    11th Circ. Backs $620K Award In Radiology Contract Fight

    The Eleventh Circuit upheld a $620,000 arbitration award in favor of an Indian teleradiology company against a radiology provider, finding the arbitrator did not exceed his authority by interpreting the parties' long-standing services agreement.

  • September 11, 2026

    Australian Bill Would Hone R&D Tax Credit To Newer Firms

    The Australian government is seeking input on a bill that would narrow eligibility for its research and development tax credit to newer firms while raising the value of the credit for businesses that qualify, the Department of the Treasury said Friday.

  • September 11, 2026

    Mass. Fund Says It Was Sidelined After Lining Up $300M

    A Massachusetts life sciences investment fund says SPRIM Global Investments strung it along on a pledge to bring it in as a co-general partner in a new joint fund, then backed out of the agreement and took control of the fund after the plaintiff lined up a $300 million investment, according to a lawsuit filed in Massachusetts state court.

  • September 11, 2026

    Fed. Circ. Questions Medical Training Co.'s $100M Deal Theory

    A medical training startup urged the Federal Circuit on Friday to revive claims accusing Galderma of a "classic catch-and-kill strategy" to derail what it says could have been a $100 million deal with Allergan, but a three-judge panel questioned whether that theory had been properly presented below.

  • September 11, 2026

    Fed. Circ. Agrees Globus Didn't Infringe Spinal Surgery IP

    The Federal Circuit on Friday upheld a Pennsylvania federal judge's decisions clearing Globus Medical Inc. of infringing Moskowitz Family LLC spinal surgery tool patents, agreeing that language used in the patents' opening statement, or preamble, limited their scope.

  • September 11, 2026

    REIT Defeats Class Claims Over $2.2B Property Impairments

    A California federal judge dismissed a proposed securities class action against Alexandria Real Estate Equities Inc., finding the investors didn't sufficiently allege that the REIT's executives misled them about $2.2 billion worth of property impairments.

  • September 10, 2026

    Lilly Owes Nektar $1B If It Breached Rezpeg Deal, Jury Told

    Nektar Therapeutics' damages expert told a California federal jury on Thursday that Eli Lilly & Co. could owe the biotechnology company nearly $1 billion if it finds that the pharmaceutical giant breached a license agreement to co-develop Nektar's autoimmune-disease drug Rezpeg.

  • September 10, 2026

    Orthopedics Co. Investor Says Docs Hid 'Boys Club' Culture

    Terminated executives of Texas-based orthopedics company Orthofix Medical Inc. have been hit with a shareholder's derivative suit accusing them of damaging the company by attempting to conceal the culture of workplace harassment they perpetuated before and after a merger.

  • September 10, 2026

    RJ Reynolds Wants In On Suit Over FDA Vape Review Rule

    Vape and nicotine pouch subsidiaries owned by Altria and R.J. Reynolds are looking to upend the U.S. Food and Drug Administration's premarket authorization rule, claiming the agency is breaking the law by dragging out product reviews well past the statutory deadline, which delays their goods by years while illegal Chinese products flood the market.

  • September 10, 2026

    Clinical Trial Buyer Says Ex-Owner Breached $100M Deal

    Surge ECN Holdings LLC and ECN Operating LLC have accused the former owner of a clinical trial research network of violating a five-year noncompete and other restrictions tied to a deal worth more than $100 million, alleging he diverted customers, recruited key physicians and used confidential information to build a competing business.

  • September 10, 2026

    Apple Watch Ban In Masimo ITC Patent Case Hits High Court

    Apple Inc. has told the U.S. Supreme Court that the Federal Circuit improperly "lowered the bar" for meeting the U.S. International Trade Commission's domestic industry requirement in patent disputes, by affirming a decision that the Apple Watch infringed Masimo Corp. patents.

  • September 10, 2026

    Dompé To Pay $32M Over Foundation Co-Pay Kickback Claims

    The U.S. arm of Italian pharmaceutical company Dompé Farmaceutici SpA has agreed to pay $32 million to resolve allegations that it contributed funds to patient assistance foundations to induce purchases of its prescription eye drops Oxervate, the U.S. Department of Justice announced Thursday.

  • September 10, 2026

    Biosimilars Boast Big Savings But Face IP Risks, Report Says

    There are no biosimilar drugs in development for 90% of biologic products set to lose their patent exclusivity by 2034, according to a report released Thursday by the Association for Accessible Medicines, which warned that current patent policy threatens generic-drug development. 

  • September 10, 2026

    Squires Grants 10 Patent Reviews, Rejects None

    U.S. Patent and Trademark Office Director John Squires has instituted 10 more Patent Trial and Appeal Board petitions, largely in the pharmaceutical space.

  • September 10, 2026

    Colo. Judge Asked To Sanction Hospital In Gender Care Suit

    Transgender adolescent patients of Children's Hospital Colorado urged a state judge on Thursday to sanction the hospital for refusing to resume providing gender-affirming medical care for transgender youth patients, arguing that the hospital can't avoid its obligation to provide the care by blaming its providers.

Expert Analysis

  • Series

    Competing At Poker Makes Me A Better Lawyer

    Author Photo

    Playing poker in male-dominated rooms taught me to treat skepticism as background noise when my opponents seem to underestimate me, to apply pressure when it matters and to adapt without losing strategic discipline — skills that are all indispensable in restructuring and insolvency matters, says Alexis Gambale at Pashman Stein.

  • Why IPR Slowdown Has Not Led To More Patent Litigation

    Author Photo

    Despite sustained strength in patent application filings and a decline in inter partes review and post-grant review, 2026 has not seen the anticipated surge in patent litigation in district courts and at the U.S. International Trade Commission, potentially due to four reasons, say attorneys at Sterne Kessler.

  • 5 Things Associates Must Ask About Their Firm's Merger Plan

    Author Photo

    The associates who navigate law firm mergers best ask the right questions early, such as inquiring about partners' plans, to assess how the merger could affect their workflow and career path, says Jackie Bokser-LeFebvre at Major Lindsey.

  • Brain Computer Interfaces Boot Up Multipronged Legal Issues

    Author Photo

    As neurotechnology companies begin to conduct human clinical trials for brain computer interfaces, attorneys should prepare for legal ramifications across a broad range of practice areas, including intellectual property, privacy and product liability, say attorneys at ArentFox Schiff.

  • Turning To The Courts When PBM Reform Falls Short

    Author Photo

    The effectiveness of state laws intended to regulate pharmacy benefit managers remains uncertain, but litigation — utilizing tried-and-true theories like breach of contract and fair dealing — offers another mechanism through which stakeholders may seek relief from PBMs, say attorneys at Reed Smith.

  • 2 'Rocket Dockets' And The Rules That Propel Them

    Author Photo

    The fastest civil trial courts in the country are currently in the Eastern District of Virginia and the Southern District of Florida, and their chief judges provide insights into the court rules that keep them ahead, says Robert Tata at Hunton.

  • Calif. Ruling Lowers Bar For Health Data Breach Claims

    Author Photo

    The California Supreme Court's ruling in J.M. v. Illuminate Education offers protection for non-healthcare companies that maintain health-related data but also adopts a new and more plaintiff-favorable standard for breach of confidentiality that companies maintaining any health-related data should address, say attorneys at Cooley.

  • Teva Ruling Offers Patentees New Support For Genus Claims

    Author Photo

    The Federal Circuit's recent decision in Teva v. Eli Lilly, finding that the Teva patents at issue are not invalid, offers an interesting counterexample against the recent trend of courts invalidating patents claiming a broad, functionally defined class of compounds, say attorneys at Cooley.

  • Your Next Litigation Hold Should Cover AI Chat Logs

    Author Photo

    The Delaware Chancery Court’s recent decision in Fortis Advisors v. Krafton to treat a CEO’s artificial intelligence chats as substantive evidence is being read as a discovery warning to litigators, but there is a second duty-to-preserve lesson that is especially pertinent to in-house counsel, say attorneys at Faegre Drinker.

  • Opinion

    High Court's Abortion Pill Stay Reinforces Appellate Principles

    Author Photo

    The U.S. Supreme Court's recent order in Danco Laboratories v. Louisiana, staying a Fifth Circuit ruling that reinstated an in-person requirement for dispensing the abortion medicine mifepristone, should be seen not as a definitive ruling on reproductive rights, but as an affirmation of a more disciplined jurisdictional reality, says Daniel Nardo at Nardo & Associates.

  • Cannabis Policy Shift May Reshape Banking, Insolvency Risks

    Author Photo

    The Trump administration's cannabis rescheduling initiative aims to correct classification that had rendered federal banking, tax administration and insolvency law incoherent, and will begin to restore some alignment between federal law and the economic reality of the marijuana industry, says Richard Ormond at Buchalter.

  • Opinion

    International Patent Licensing System Must Be Maintained

    Author Photo

    As foreign approaches to patent enforcement threaten to distort the licensing markets that underpin modern technology, courts and policymakers must take action to ensure that the standard essential patent framework is preserved, says Brian O'Shaughnessy at Dinsmore.

  • Series

    Studying Foreign Languages Makes Me A Better Lawyer

    Author Photo

    Studying Italian and Japanese has shown me that learning a new language can benefit a legal career in several ways, including by demonstrating the importance of approaching problems from a fresh perspective and the value of practicing patience with colleagues and clients, says Anna King at Genworth Financial.

  • 10 US Patent Pressure Points For EU Life Sciences Cos.

    Author Photo

    U.S.-specific patent issues can be challenging for European life sciences companies because they require decisions at the intersection of legal, scientific, regulatory and commercial functions, necessitating proactive, cross-functional steps from EU patent counsel, says Paul Calvo at Sterne Kessler.

  • Sizing Up The Rescheduling Hurdles Medical Pot Cos. Face

    Author Photo

    The Justice Department’s recent lowering of certain medical marijuana products to Schedule III means operators — particularly those simultaneously offering federally illegal adult-use cannabis — must implement greater structural discipline to navigate an increasingly fragmented legal landscape if they hope to benefit from new tax deductions and access to capital, say attorneys at Akerman.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.